Applicant

Yousef Al-Abed

Appl. No.

10/594,641

Filed

March 28, 2008

## **Listing of Claims**

A listing of the claims, including new Claims 38 and 39 as added, is as follows:

- 1. (Previously Presented) A method of inhibiting the progression of type 1 diabetes in a mammal having type 1 diabetes, the method comprising administering to the mammal a pharmaceutical composition comprising an anti-diabetogenic amount of an agent to inhibit the progression of type 1 diabetes in the mammal, wherein the agent comprises a binding site of an antibody that binds specifically to macrophage migration inhibitory factor (MIF).
  - 2. (Canceled).
- 3. (Previously Presented) The method of claim 1, wherein the agent is an antibody.
  - 4-10. (Canceled).
- 11. (Previously Presented) The method of claim 1, wherein the mammal is a human.
  - 12-26. (Canceled).
- 27. (Previously Presented) The method of claim 3, wherein the antibody is a monoclonal antibody.
- 28. (Previously Presented) The method of claim 3, wherein the antibody is a humanized antibody.

Applicant

Yousef Al-Abed

Appl. No.

10/594,641

Filed

March 28, 2008

29. (Previously presented) A method of inhibiting the development of type 1 diabetes in a mammal at risk for type 1 diabetes, the method comprising administering to the mammal a pharmaceutical composition comprising an amount of an agent effective to inhibit the development of type 1 diabetes in a mammal at risk for type 1 diabetes, wherein the agent comprises a binding site of an antibody that binds specifically to macrophage migration inhibitory factor (MIF).

- 30. (Previously presented) The method of claim 29, wherein the agent is an antibody.
- 31. (Previously presented) The method of claim 29, wherein the mammal is a human.
- 32. (Previously presented) The method of claim 29, wherein the antibody is a monoclonal antibody.
- 33. (Previously presented) The method of claim 29, wherein the antibody is a humanized antibody.
- 34. (Previously Presented) The method of claim 1, wherein the agent is an Fab fragment of an antibody.
- 35. (Previously Presented) The method of claim 1, wherein the agent is an F(ab)<sub>2</sub> fragment of an antibody.
- 36. (Previously Presented) The method of claim 29, wherein the agent is an Fab fragment of an antibody.

Applicant

Yousef Al-Abed

Appl. No.

10/594,641

Filed

March 28, 2008

37. (Previously Presented) The method of claim 29, wherein the agent is an  $F(ab)_2$  fragment of an antibody.

- 38. (New) The method of Claim 1, wherein administration of the agent effects a reduction in hyperglcycemia in a mammal having type 1 diabetes.
- 39. (New) The method of Claim 29, wherein inhibition of development of type 1 diabetes is effected by the mammal at risk remaining euglycemic.